Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes

Transplantation

Volumn 78, Issue 5, 2004, Pages 755-757

  Pakakasama, Samart ^a   Eames, Gretchen M ^b   Morriss, Michael C ^c   Huls, M Helen ^d   Rooney, Cliona M ^d   Heslop, Helen E ^d   Krance, Robert A ^d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Cook Children's Medical Center ^*  (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Cytotoxic T cell lymphocytes; Epstein Barr virus; Hematopoietic stem cell transplantation; Hydroxyurea; Lymphoproliferative disease

Indexed keywords

FLUDARABINE; HYDROXYUREA; MELPHALAN; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ANAMNESIS; ARTICLE; BRAIN INJURY; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC IMAGING; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HURLER SYNDROME; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; SPLEEN DISEASE;

ADULT; BRAIN; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; HYDROXYUREA; LYMPHOCYTE TRANSFUSION; LYMPHOPROLIFERATIVE DISORDERS; MUCOPOLYSACCHARIDOSIS I; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 4544344289     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000129813.54517.25     Document Type: Article

References (12)

1. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999; 94: 2208-2216.
2. Lucas K, Small T, Heller G, et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87: 2594-2603.
3. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502-1505.
4. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000; 11(suppl 1): 113-116.
5. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555.
6. Slobod KS, Taylor GH, Sandlund JT, et al. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 2000; 356: 1493-1494.
7. Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002; 100: 4059-4066.
8. Gottschalk S, Edwards OL, Sili U, et al. Generating CTL against the subdominant Epstein-Barr virus LMP 1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003; 101: 1905-1912.
9. Heslop HE, Ng CYC, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-555.
10. Von Hoff DD, McGill JR, Forseth BJ, et al. Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad Sci USA 1992; 89: 8165-8169.
11. Chodosh J, Holder VP, Gan Y-J, et al. Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. J Infect Dis 1998; 177: 1194-1201.
12. Gottschalk S, Heslop HE, Rooney CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 2002; 84: 175-201.